|
Neoplasms
|
0.040 |
GeneticVariation
|
group |
BEFREE |
We examined the mRNA expression of C terminus-binding protein-interacting protein and Lin11, Isl-1, and Mec-3 domain only 4 (LMO4) in pretreatment tumor samples from 91 erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations in whom breast cancer gene 1 (BRCA1) expression and the concomitant presence of the EGFR T790M mutation had previously been assessed.
|
23407556 |
2013 |
|
Breast Carcinoma
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
We examined the mRNA expression of C terminus-binding protein-interacting protein and Lin11, Isl-1, and Mec-3 domain only 4 (LMO4) in pretreatment tumor samples from 91 erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations in whom breast cancer gene 1 (BRCA1) expression and the concomitant presence of the EGFR T790M mutation had previously been assessed.
|
23407556 |
2013 |
|
Central neuroblastoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
In the present study, we validated the ability of 14 commonly used real-time RT-PCR markers to detect MRD based on their expression in neuroblastoma TICs, and we developed a novel MRD detection protocol, which scored the samples as MRD-positive when the expression of one of the 11 real-time RT-PCR markers (CHRNA3, CRMP1, DBH, DCX, DDC, GABRB3, GAP43, ISL1, KIF1A, PHOX2B and TH) exceeded the normal range.
|
23417100 |
2013 |
|
Childhood Neuroblastoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
In the present study, we validated the ability of 14 commonly used real-time RT-PCR markers to detect MRD based on their expression in neuroblastoma TICs, and we developed a novel MRD detection protocol, which scored the samples as MRD-positive when the expression of one of the 11 real-time RT-PCR markers (CHRNA3, CRMP1, DBH, DCX, DDC, GABRB3, GAP43, ISL1, KIF1A, PHOX2B and TH) exceeded the normal range.
|
23417100 |
2013 |
|
Ventricular Septal Defects
|
0.030 |
GeneticVariation
|
group |
BEFREE |
These findings suggest that ISL1 genetic polymorphisms are associated with occurrence of VSD, thus they may be useful as molecular markers for prediction of VSD.
|
23572340 |
2013 |
|
Arrhythmogenic Right Ventricular Dysplasia
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
In this study we evaluated whether ISL1 variants are associated with hypertrophic (HCM), dilated (DCM), arrhythmogenic right ventricular cardiomyopathy (ARVC), or with Emery-Dreifuss muscular dystrophy (EDMD).
|
23152444 |
2013 |
|
Muscular Dystrophy, Emery-Dreifuss
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In this study we evaluated whether ISL1 variants are associated with hypertrophic (HCM), dilated (DCM), arrhythmogenic right ventricular cardiomyopathy (ARVC), or with Emery-Dreifuss muscular dystrophy (EDMD).
|
23152444 |
2013 |
|
Abnormality of cardiovascular system morphology
|
0.010 |
Biomarker
|
disease |
BEFREE |
The LIM homeodomain transcriptor factor ISL1 is a marker for undifferentiated cardiac progenitor cells that give rise to both the right ventricle and the inflow and outflow tracts, which are affected by several cardiovascular malformations.
|
23229290 |
2013 |
|
Coronary heart disease
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
We concluded that rs1017 contributed to the risk of CHD in Chinese Han people, and ISL1 may be involved in the formation and development of the heart.
|
24634231 |
2014 |
|
Congenital heart disease
|
0.060 |
GeneticVariation
|
group |
BEFREE |
Genetic variations of ISL1 associated with human congenital heart disease in Chinese Han people.
|
24634231 |
2014 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
However, how ISL-1 exerts the role in tumor development is not clear.
|
25070240 |
2014 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Recent studies indicate that ISL-1 may also involve in the occurrence of a variety of tumors.
|
24845569 |
2014 |
|
Congenital Abnormality
|
0.030 |
GeneticVariation
|
group |
BEFREE |
In the TOF patients, we found four copy number gains affecting three genes, of which two are important regulators of heart development (NOTCH1, ISL1) and one is located in a region associated with cardiac malformations (PRODH at 22q11).
|
24400131 |
2014 |
|
Ventricular Septal Defects
|
0.030 |
Biomarker
|
group |
BEFREE |
ISL1 is related to the atrial septal defect group and the ventricular septal defect group, and the genotypes were associated with the occurrence of CHD in the dominant mode of inheritance.
|
24634231 |
2014 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Further study revealed that ISL-1 promoted the proliferation of pancreatic β-cells and DLBCL cells, and also accelerated the tumorigenesis of DLBCL in vivo.
|
24845569 |
2014 |
|
Atrial Septal Defects
|
0.010 |
Biomarker
|
group |
BEFREE |
ISL1 is related to the atrial septal defect group and the ventricular septal defect group, and the genotypes were associated with the occurrence of CHD in the dominant mode of inheritance.
|
24634231 |
2014 |
|
Hodgkin Disease
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemistry results demonstrated a markedly higher expression of ISL-1 in 75% of non-Hodgkin lymphoma (NHL) samples compared with that in normal lymph nodes or Hodgkin lymphoma (HL) samples.
|
25070240 |
2014 |
|
Lymphoma
|
0.010 |
AlteredExpression
|
group |
BEFREE |
The results showed that ISL-1 overexpression obviously promoted NHL cells proliferation, changed the cell cycle distribution in vitro and significantly enhanced xenografted lymphoma development in vivo.
|
25070240 |
2014 |
|
Lymphoma, Non-Hodgkin
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Real-time PCR, Western blot, luciferase assay and ChIP assay were used to explore the potential regulatory targets of ISL-1 and the results demonstrated that ISL-1 activated the c-Myc expression in NHL by direct binding to a conserved binding site on the c-Myc enhancer.
|
25070240 |
2014 |
|
Diffuse Large B-Cell Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, our results demonstrate a positive feedback regulation of ISL-1 in DLBCL but not in pancreatic β-cells, which might result in the functional diversities of ISL-1 in different physiological and pathological processes.
|
24845569 |
2014 |
|
Adult Hodgkin Lymphoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemistry results demonstrated a markedly higher expression of ISL-1 in 75% of non-Hodgkin lymphoma (NHL) samples compared with that in normal lymph nodes or Hodgkin lymphoma (HL) samples.
|
25070240 |
2014 |
|
Adult Non-Hodgkin Lymphoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
ISL-1 is overexpressed in non-Hodgkin lymphoma and promotes lymphoma cell proliferation by forming a p-STAT3/p-c-Jun/ISL-1 complex.
|
25070240 |
2014 |
|
Childhood Non-Hodgkin Lymphoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
ISL-1 is overexpressed in non-Hodgkin lymphoma and promotes lymphoma cell proliferation by forming a p-STAT3/p-c-Jun/ISL-1 complex.
|
25070240 |
2014 |
|
Childhood Hodgkin Lymphoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemistry results demonstrated a markedly higher expression of ISL-1 in 75% of non-Hodgkin lymphoma (NHL) samples compared with that in normal lymph nodes or Hodgkin lymphoma (HL) samples.
|
25070240 |
2014 |
|
Adult Lymphoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The results showed that ISL-1 overexpression obviously promoted NHL cells proliferation, changed the cell cycle distribution in vitro and significantly enhanced xenografted lymphoma development in vivo.
|
25070240 |
2014 |